Gao Fangyuan, Li Xiaoshu, Wan Gang, Li Yuxin, Zhang Qun, Liu Yao, Liu Huimin, Li Hai, Wang Xianbo
Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Statistics Room, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
BMC Gastroenterol. 2018 Dec 3;18(1):179. doi: 10.1186/s12876-018-0911-y.
Acute decompensation (AD) has been shown to be associated with a high mortality rate for cirrhosis patients. This study aimed to develop a prognostic nomogram to evaluating the individual prognosis for AD of cirrhosis in chronic hepatitis B (CHB).
The nomogram was developed using data from a retrospective study on 509 patients hospitalized for AD of CHB cirrhosis from October 2008 to February 2014 at the Beijing Ditan Hospital, Capital Medical University. The predictive accuracy, discriminative ability, and clinical net benefit were evaluated by concordance index (C-index), calibration curves, and decision curve analysis (DCA). The results were validated on 620 patients consecutively enrolled from January 2005 to December 2010 at the Renji Hospital, Shanghai Jiao Tong University,.
On multivariate analysis of the derivation cohort, independent factors included in the nomogram were age, previous decompensation, bacterial infection, hepatic encephalopathy, and total bilirubin. The calibration curve for the probability of survival showed good agreement between the nomogram and actual observation. The nomogram had a C-index of 0.897, which was statistically higher than the C-index values of CTP (0.793), MELD (0.821), SOFA (0.868), or the Chronic Liver Failure Consortium AD (CLIF-C AD) (0.716) scores (p < 0.001 for all). Using DCA, the nomogram also demonstrated superior net benefits over other score models. The results were confirmed in the validation cohort.
The proposed nomogram enables more-accurate individualized prediction of survival than MELD, CTP, SOFA, or CLIF-C AD scores for AD of CHB cirrhosis patients.
急性失代偿(AD)已被证明与肝硬化患者的高死亡率相关。本研究旨在开发一种预后列线图,以评估慢性乙型肝炎(CHB)肝硬化患者AD的个体预后。
该列线图是使用2008年10月至2014年2月在北京地坛医院住院治疗的509例CHB肝硬化AD患者的回顾性研究数据开发的。通过一致性指数(C指数)、校准曲线和决策曲线分析(DCA)评估预测准确性、判别能力和临床净效益。结果在上海交通大学医学院附属仁济医院2005年1月至2010年12月连续纳入的620例患者中得到验证。
在推导队列的多因素分析中,列线图纳入的独立因素包括年龄、既往失代偿、细菌感染、肝性脑病和总胆红素。生存概率的校准曲线显示列线图与实际观察结果之间具有良好的一致性。列线图的C指数为0.897,在统计学上高于CTP(0.793)、MELD(0.821)、SOFA(0.868)或慢性肝衰竭联盟AD(CLIF-C AD)(0.716)评分的C指数值(所有p均<0.001)。使用DCA,列线图也显示出比其他评分模型更好的净效益。结果在验证队列中得到证实。
对于CHB肝硬化患者的AD,所提出的列线图比MELD、CTP、SOFA或CLIF-C AD评分能够更准确地进行个体生存预测。